

University of Groningen

Preclinical molecular imaging to study the biodistribution of antibody derivatives in oncology

Warnders, Jan Feije

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Warnders, J. F. (2018). *Preclinical molecular imaging to study the biodistribution of antibody derivatives in oncology*. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

**Preclinical molecular imaging to study the
biodistribution of antibody derivatives in oncology**

Frank-Jan Warnders

Warnders, F.J.

Preclinical molecular imaging to study the biodistribution of antibody derivatives in oncology

Thesis, University of Groningen, Groningen, The Netherlands

© Frank-Jan Warnders, 2018

Copyright of the published articles is with the corresponding journal or otherwise with the author. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing from the author or the copyright-owning journal.

Cover Remco Wetzels

Layout Maroesja Swart-Nijhuis | Puur*M

Printed by Gildeprint

The research in this thesis is financially supported by European Research Council (ERC) Advanced grant OnQview, Dutch Cancer Society grant (RUG 2010 4739), Center for Translational Molecular Medicine grant (MAMMOTH), Amgen and Merck Biopharma.

Publication of this thesis was financially supported by the department of Clinical Pharmacy and Pharmacologie of the University Medical Center Groningen, Ziekenhuisgroep Twente, University of Groningen, Graduate School of Medical Sciences and the University Medical Center Groningen.



rijksuniversiteit
groningen

Preclinical molecular imaging to study the biodistribution of antibody derivatives in oncology

Proefschrift

Ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. E. Sterken
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 04 juli 2018 om 14.30 uur

door

Jan Feije Warnders

geboren op 27 maart 1985
te Assen

Promotores

Prof. dr. J.G.W. Kosterink

Prof. dr. E.G.E. de Vries

Copromotor

Dr. M.N. Lub – de Hooge

Beoordelingscommissie

Prof. dr. N.H. Hendrikse

Prof. dr. P.H. Elsinga

Prof. dr. J.A. Gietema

Contents

Chapter 1	9
General introduction	
Chapter 2	19
Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives and non-Ig scaffolds. <i>Med Res Rev. 2018 [Epub ahead of print]</i>	
Chapter 3	71
Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. <i>Eur J Nucl Med Mol Imaging. 2013;40(11):1718-29</i>	
Chapter 4	99
HER3-specific tumor uptake and biodistribution of ⁸⁹ Zr-MSB0010853 visualized by real-time and non-invasive PET imaging. <i>J Nucl Med. 2017;58(8):1210-1215</i>	
Chapter 5	117
Biodistribution and PET imaging of labeled bispecific T cell-engaging antibody targeting EpCAM. <i>J Nucl Med. 2016;57(5):812-7.</i>	
Chapter 6	143
Molecular imaging of radiolabeled bispecific T-cell engager ⁸⁹ Zr-AMG211 targeting CEA-positive tumors. <i>Submitted</i>	
Chapter 7	167
General discussion and future perspectives	
Chapter 8	173
Summary	
Chapter 9	179
Nederlandse samenvatting	
Dankwoord	186
About the author	190

